home / stock / asln / asln articles
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused bi...
SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceutical (NASDAQ:ASLN), a clinical-stage, immunology-focused bio...
New Composition of Matter Patent for farudodstat would strengthen intellectual property protection and provide commercial exclusivity for farudod...
Following the successful TREK-AD Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, process is underway to identify potential...
SAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology focused bio...
Head-to-head study between eblasakimab and dupilumab in skin biopsies from atopic dermatitis (AD) patients confirm eblasakimab's differentia...
ASLAN management will present emerging data from the TREK-AD study and new market research data on the AD treatment landscape from patient and pr...
SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused bi...
News, Short Squeeze, Breakout and More Instantly...
ASLAN Pharmaceuticals Limited Company Name:
ASLN Stock Symbol:
NASDAQ Market:
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused bi...
SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on eblasakimab in Chro...
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab -experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Ar...